| 1 |
26734075 | Effects of nateglinide and rosiglitazone on pancreatic alpha- and beta-cells, GLP-1 secretion and inflammatory markers in patients with type 2 diabetes: randomized crossover clinical study. | 2016 |
1 |
| 2 |
23408783 | Combination of peroxisome proliferator-activated receptor α/γ agonists may benefit type 2 diabetes patients with coronary artery disease through inhibition of inflammatory cytokine secretion. | 2013 Mar |
1 |
| 3 |
22659808 | Rosiglitazone inhibits angiotensin II-induced C-reactive protein production in human aortic endothelial cells through regulating AT(1)-ROS-MAPK signal pathway. | 2012 Sep |
3 |
| 4 |
21383592 | Rosiglitazone regulates c-reactive protein-induced inflammatory responses via glucocorticoid receptor-mediated inhibition of p38 mitogen-activated protein kinase-toll-like receptor 4 signal pathway in vascular smooth muscle cells. | 2011 Mar |
7 |
| 5 |
19808911 | Rosiglitazone decreases C-reactive protein to a greater extent relative to glyburide and metformin over 4 years despite greater weight gain: observations from a Diabetes Outcome Progression Trial (ADOPT). | 2010 Jan |
4 |
| 6 |
20233517 | Peroxisome proliferator-activated receptor-gamma(PPARgamma) agonist improves coronary artery endothelial function in diabetic patients with coronary artery disease. | 2010 Jan-Feb |
1 |
| 7 |
20926154 | The impacts of thiazolidinediones on circulating C-reactive protein levels in different diseases: a meta-analysis. | 2010 Dec |
3 |
| 8 |
18758684 | Effect of pioglitazone and rosiglitazone on mediators of endothelial dysfunction, markers of angiogenesis and inflammatory cytokines in type-2 diabetes. | 2009 Mar |
1 |
| 9 |
19394661 | Impact of rosiglitazone and glyburide on nitrosative stress and myocardial blood flow regulation in type 2 diabetes mellitus. | 2009 Jul |
1 |
| 10 |
19812444 | Combined effect of C-reactive protein and stavudine on adipogenesis. | 2009 |
1 |
| 11 |
18541328 | The effect of rosiglitazone on oxidative stress and insulin resistance in overweight individuals. | 2008 Aug |
1 |
| 12 |
17074328 | Rosiglitazone treatment alleviates inflammation and improves liver function in overweight women with polycystic ovary syndrome: a randomized placebo-controlled study. | 2007 Jan |
1 |
| 13 |
17307426 | A randomized trial of the effects of rosiglitazone and metformin on inflammation and subclinical atherosclerosis in patients with type 2 diabetes. | 2007 Mar |
1 |
| 14 |
17517066 | Rosiglitazone RECORD study: glucose control outcomes at 18 months. | 2007 Jun |
2 |
| 15 |
17584566 | Peroxisome proliferator-activated receptor gamma agonists for the Prevention of Adverse events following percutaneous coronary Revascularization--results of the PPAR study. | 2007 Jul |
1 |
| 16 |
17641277 | C-reactive protein inhibits adiponectin gene expression and secretion in 3T3-L1 adipocytes. | 2007 Aug |
1 |
| 17 |
17884451 | Peroxisome proliferator-activated receptor gamma agonist improves arterial stiffness in patients with type 2 diabetes mellitus and coronary artery disease. | 2007 Oct |
1 |
| 18 |
18048467 | Rosiglitazone improves endothelial function and inflammation but not asymmetric dimethylarginine or oxidative stress in patients with type 2 diabetes mellitus. | 2007 Nov |
2 |
| 19 |
16253380 | Improvement in C-reactive protein and advanced glycosylation end-products in poorly controlled diabetics is independent of glucose control. | 2006 Apr |
1 |
| 20 |
16410460 | Effect of rosiglitazone treatment on plaque inflammation and collagen content in nondiabetic patients: data from a randomized placebo-controlled trial. | 2006 Apr |
1 |
| 21 |
16546473 | Rosiglitazone improves insulin sensitivity in nonobese subjects with impaired glucose tolerance: the role of adiponectin and C-reactive protein. | 2006 Apr |
3 |
| 22 |
16751941 | [Effects of rosiglitazone on endothelial function in non-diabetic subjects with metabolic syndrome]. | 2006 May |
1 |
| 23 |
16939632 | C-reactive protein (CRP)-lowering agents. | 2006 Spring |
1 |
| 24 |
16957566 | Rosiglitazone reduces microalbuminuria and blood pressure independently of glycemia in type 2 diabetes patients with microalbuminuria. | 2006 Oct |
1 |
| 25 |
17027571 | Relation of improvement in endothelium-dependent flow-mediated vasodilation after rosiglitazone to changes in asymmetric dimethylarginine, endothelin-1, and C-reactive protein in nondiabetic patients with the metabolic syndrome. | 2006 Oct 15 |
4 |
| 26 |
17160915 | Rosiglitazone increases LDL particle size and buoyancy and decreases C-reactive protein in patients with type 2 diabetes on statin therapy. | 2006 Dec |
2 |
| 27 |
15708106 | Endothelial inflammation in insulin resistance. | 2005 Feb 12-18 |
1 |
| 28 |
15985490 | Free fatty acid-induced insulin resistance in the obese is not prevented by rosiglitazone treatment. | 2005 Sep |
1 |
| 29 |
15994753 | Effect of rosiglitazone on insulin resistance, C-reactive protein and endothelial function in non-obese young women with polycystic ovary syndrome. | 2005 Jul |
1 |
| 30 |
16125536 | The effect of rosiglitazone on novel atherosclerotic risk factors in patients with type 2 diabetes mellitus and hypertension. An open-label observational study. | 2005 Sep |
1 |
| 31 |
16183427 | Rosiglitazone reduces insulin requirement and C-reactive protein levels in type 2 diabetic patients receiving peritoneal dialysis. | 2005 Oct |
3 |
| 32 |
14759393 | Effects of rosiglitazone on endothelial function, C-reactive protein, and components of the metabolic syndrome in nondiabetic patients with the metabolic syndrome. | 2004 Feb 1 |
1 |
| 33 |
15078802 | C-reactive protein attenuates endothelial progenitor cell survival, differentiation, and function: further evidence of a mechanistic link between C-reactive protein and cardiovascular disease. | 2004 May 4 |
2 |
| 34 |
15181049 | Evidence for a potent antiinflammatory effect of rosiglitazone. | 2004 Jun |
1 |
| 35 |
15246889 | Effects of rosiglitazone on endothelial function in men with coronary artery disease without diabetes mellitus. | 2004 Jul 15 |
1 |
| 36 |
15505001 | Preventative effects of rosiglitazone on restenosis after coronary stent implantation in patients with type 2 diabetes. | 2004 Nov |
1 |
| 37 |
12661797 | Rosiglitazone: potential beneficial impact on cardiovascular disease. | 2003 Mar |
1 |
| 38 |
12667961 | Vascular smooth muscle cell activation by C-reactive protein. | 2003 Apr 1 |
1 |
| 39 |
12689821 | Hyperglycemia potentiates the proatherogenic effects of C-reactive protein: reversal with rosiglitazone. | 2003 Apr |
3 |
| 40 |
12957323 | Insulin resistance, inflammation, and the prediabetic state. | 2003 Aug 18 |
1 |
| 41 |
14642684 | The effects of rosiglitazone, a peroxisome proliferator-activated receptor-gamma agonist, on markers of endothelial cell activation, C-reactive protein, and fibrinogen levels in non-diabetic coronary artery disease patients. | 2003 Nov 19 |
2 |
| 42 |
12163427 | Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. | 2002 Aug 6 |
3 |